Journal article

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G Horvath, Kate L Mahon, Edmond M Kwan, Heidi Fettke, Jianjun Yu, Arun A Azad

EBioMedicine | ELSEVIER | Published : 2020

Abstract

BACKGROUND: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbations. The aim of this study was to identify cell free DNA- (cfDNA-) based alterations and their associations with outcomes in progressive metastatic prostate cancer. METHODS: In this longitudinal prospective cohort study plasma cfDNA/circulating tumor DNA (ctDNA) was analyzed before, during, and after androgen deprivation therapy (ADT) in 4 independent patient groups ranging from untreated metastatic hormone sensitive prostate cancer (mHSPC) to metastatic castrate resistant prostate cancer (mCRPC). Next generation sequencing was performed on ctDNA and germline DNA to..

View full abstract

Grants

Awarded by NHMRC


Awarded by Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow


Awarded by Cancer Institute NSW Translational Program


Awarded by Victorian Cancer Agency Clinical Research Fellowship


Awarded by National Institute of Health


Funding Acknowledgements

This study was supported by: NHMRC Postgraduate Scholarship (to EdmondMKwan); Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow (CSA 0515; to Kate Mahon); the Astellas Investigator-Initiated Grant, Cancer Institute NSW Translational Program Grant (2018/TPG001; to Lisa G Horvath); the NHMRC Project Grant, Victorian Cancer Agency Clinical Research Fellowship-CRF14009, Astellas Investigator-Initiated Grant, NHMRC Project Grant - GNT1098647 (to Arun A Azad); and the National Institute of Health-RO1-CA212097 (to Manish Kohli).